Article
Pharmacology & Pharmacy
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Summary: This study compared the relative survival rate of gefitinib, erlotinib, and afatinib in EGFR-mutated advanced lung adenocarcinoma patients in Taiwan. Afatinib showed better overall survival and time to treatment failure outcomes compared to gefitinib and erlotinib, especially in patients with initial brain metastases.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Chunsheng Wang, Kewei Zhao, Shanliang Hu, Wei Dong, Yan Gong, Minghuan Li, Conghua Xie
Summary: By studying the outcomes of gefitinib and erlotinib in patients with uncommon EGFR mutations in non-small cell lung cancer (NSCLC), it was found that patients with compound mutations had better treatment response, with those containing exon 19 deletion or L858R mutations showing the most significant benefits in response and survival. Additionally, the gefitinib group showed superior treatment efficacy and PFS benefit compared to the erlotinib group.
Article
Oncology
Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura
Summary: The study found that both first- and second-generation EGFR-TKIs have favorable responses in NSCLC patients with uncommon EGFR mutations. Patients with G719X mutation had a more favorable progression-free survival compared to those with L861Q mutation and compound mutations. EGFR-TKIs not only present favorable responses but also contribute to long-term disease control in NSCLC patients with uncommon EGFR mutations, surpassing the effects of cytotoxic chemotherapy and immune checkpoint inhibitors.
Article
Oncology
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Summary: This study evaluated the efficacy of EGFR-TKIs for NSCLC patients with uncommon EGFR mutations and identified prognostic factors. The results showed that afatinib demonstrated better survival outcomes than gefitinib/erlotinib for these patients.
Review
Oncology
Edward S. Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C-H Yang
Summary: Data comparing outcomes of different EGFR tyrosine kinase inhibitors in Asian patients with EGFR mutation-positive non-small-cell lung cancer are limited. While first- and second-generation TKIs show similar outcomes in Asian and non-Asian populations, the third-generation TKI osimertinib does not confer the same overall survival benefit in Asians, particularly in well-resourced countries like Japan. Head-to-head comparisons of second- and third-generation EGFR TKIs should be considered in Asia.
Article
Oncology
Ciric To, Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala, Bo H. Shin, David E. Heppner, Jaimin K. Rana, Brittaney A. Leeper, Kara M. Soroko, Michael J. Poitras, Prafulla C. Gokhale, Yoshihisa Kobayashi, Kamal Wahid, Kari J. Kurppa, Thomas W. Gero, Michael D. Cameron, Atsuko Ogino, Mierzhati Mushajiang, Chunxiao Xu, Yanxi Zhang, David A. Scott, Michael J. Eck, Nathanael S. Gray, Pasi A. Janne
Summary: Researchers have discovered a new EGFR inhibitor, JBJ-09-063, which shows efficacy against therapy-resistant mutations in EGFR-mutant lung cancer. The study also found that the resistance to JBJ-09-063 is caused by EGFR homo- or heterodimerization and specific mutations.
Article
Chemistry, Medicinal
Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Aysegul Ozen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm, Thomas A. Dineen
Summary: While EGFR tyrosine kinase inhibitors have revolutionized the treatment of NSCLC, the development of resistance mutations remains a challenge. This study introduces a novel reversible inhibitor, BLU-945, that shows promising activity against different resistance mutations. Clinical trials are currently underway to evaluate its efficacy and safety.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Critical Care Medicine
Shun Lu, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu
Summary: This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line treatment for patients with EGFR mutation-positive NSCLC. The study found that befotertinib demonstrated superior efficacy in terms of progression-free survival compared to icotinib, although it was associated with more frequent adverse events.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Oncology
K. Tamura, T. Yoshida, K. Masuda, Y. Matsumoto, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Summary: This retrospective study investigated the activity of EGFR-TKIs in untreated EGFR-mutated NSCLC patients with leptomeningeal metastases (LM). The results showed that osimertinib had better outcomes in LM compared to first-generation TKIs, especially in patients with exon 19 deletion.
Article
Oncology
R. B. Verheijen, T. T. van Duijl, M. M. van den Heuvel, D. Vessies, M. Muller, J. H. Beijnen, J. M. Janssen, J. H. M. Schellens, N. Steeghs, D. van den Broek, A. D. R. Huitema
Summary: EGFR mutations in circulating tumor DNA were quantified in 249 plasma samples from 68 NSCLC patients, showing driver mutations increased in copy number several months before disease progression. Quantification of EGFR mutations in plasma ctDNA was predictive of treatment outcomes in NSCLC patients, particularly an increase in driver mutation copy number could predict disease progression.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Oncology
Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, Naoko Okura, Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Kenji Kita, Seiji Yano, Koichi Takayama
Summary: EGFR-T790M mutation is a major mechanism of acquired resistance to EGFR-TKIs in lung cancer. The biological characteristics of T790M tumors differ based on treatment regimens with each generation of EGFR-TKI. The maintenance of EGFR dependency after acquiring resistance may depend on the type of EGFR-TKI.
Article
Chemistry, Medicinal
Chih-Hung Guo, Wen-Chin Li, Chia-Lin Peng, Pei-Chung Chen, Shih-Yu Lee, Simon Hsia
Summary: This study found that the combination of selenium/fish oil with gefitinib or erlotinib significantly reduced tumor volume and weight in lung cancer treatment, and also reduced metastasis. Furthermore, the combination treatment modulated multiple signaling pathways and immune checkpoint molecules, reduced angiogenesis, cancer stemness, epithelial to mesenchymal transitions, metastasis, and proliferation, and increased cell cycle arrest and apoptosis.
Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Sheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, Yueh-Feng Wen, Meng-Rui Lee, Ching-Yao Yang, Jann-Yuan Wang, Jen-Chung Ko, Jin-Yuan Shih, Chong-Jen Yu
Summary: The study suggests that afatinib may not provide longer overall survival compared to first-generation TKIs in patients with EGFR mutant lung adenocarcinoma, but may have a survival benefit in smokers. Pemetrexed may be the preferred choice for subsequent chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Wei Cao, Jun Ma, Xuan Jiang, Guangyi Gao
Summary: This study investigated the clinical intervention effect of afatinib targeted therapy in patients with non-small-cell lung cancer. The results showed that afatinib targeted therapy significantly improved the treatment effective rate, immune function, and serum EGFR and pro-GRP levels in patients.
Article
Oncology
S. N. Aleksakhina, M. M. Kramchaninov, A. D. Mikushina, S. E. Kubrina, V. V. Petkau, A. O. Ivantsov, V. M. Moiseyenko, E. N. Imyanitov, A. G. Iyevleva
Summary: The presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Review
Oncology
Evgeny N. Imyanitov, Aglaya G. Iyevleva, Evgeny V. Levchenko
Summary: Molecular testing is essential in NSCLC management, including detecting mutations and translocations, as well as analyzing protein expression. Efforts are ongoing to integrate multiple molecular assays into a single diagnostic pipeline for NSCLC.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Aleksei Viktorovich Novik, Svetlana Anatolievna Protsenko, Irina Alexandrovna Baldueva, Lev Michailovich Berstein, Vladimir Nikolaevich Anisimov, Irina Nikolaevna Zhuk, Anna Igorevna Semenova, Dilorom Khamidovna Latipova, Elena Viktorovna Tkachenko, Tatiana Yurievna Semiglazova
Summary: There was no evidence to suggest that melatonin and metformin could increase the efficacy of systemic chemotherapy in melanoma. Combination therapy with these two drugs did not show more benefit than monotherapy with dacarbazine. Delayed responses were observed in patients receiving the combination therapy, indicating potential involvement of the immune system in clinical activity.
Meeting Abstract
Oncology
E. N. Imyanitov, A. Venina, A. O. Ivantsov, E. S. Kuligina, A. Iyevleva, N. Savelov, G. Raskin, S. Aleksakhina
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Sergey V. Orlov, Aglaya G. Iyevleva, Elena A. Filippova, Alexandra M. Lozhkina, Svetlana V. Odintsova, Tatiana N. Sokolova, Natalia V. Mitiushkina, Vladislav I. Tiurin, Elena V. Preobrazhenskaya, Alexandr A. Romanko, Alexandr S. Martianov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Alexandr V. Togo, Evgeny N. Imyanitov
Summary: The use of lorlatinib in patients with ALK rearranged non-small cell lung cancer resulted in excellent outcomes, especially in controlling brain metastases. However, caution should be taken for patients who do not experience any adverse effects from the drug.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Aglaya G. Iyevleva, Svetlana N. Aleksakhina, Anna P. Sokolenko, Sofia Baskina, Aigul R. Venina, Elena Anisimova, Ilya Bizin, Alexandr O. Ivantsov, Yana Belysheva, Alexandra P. Chernyakova, Alexandr Togo, Evgeny N. Imyanitov
Summary: Somatic loss of the wild-type CHEK2 allele is observed in approximately half of CHEK2-driven breast cancers. Tumors without CHEK2 LOH are chromosomally stable. Breast cancers with LOH demonstrate some signs of chromosomal instability, but its degree is significantly lower compared to BRCA1/2-associated tumors.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Evgeny N. Imyanitov, Aglaya G. Iyevleva
Summary: Chemotherapy is the mainstay of cancer treatment, with predictive assays helping to personalize drug administration. Genetic deficiencies can impact tumor responsiveness to certain drugs, allowing for dosage adjustment through pharmacogenetic testing. Promising molecular predictors may lead to new clinically useful markers for cytotoxic therapy.
Article
Genetics & Heredity
Igor E. Orlov, Tatiana A. Laidus, Anastasia Tumakova, Grigoriy A. Yanus, Aglaya G. Iyevleva, Anna P. Sokolenko, Ilya Bizin, Evgeny N. Imyanitov, Evgeny N. Suspitsin
Summary: Whole exome sequencing is a powerful tool for identifying population-specific genetic diseases. This study found recurrent pathogenic alleles in a small number of individual Russian exomes, with some being non-Russian-specific and others characteristic for subjects of Russian origin.
EUROPEAN JOURNAL OF MEDICAL GENETICS
(2022)
Article
Oncology
Natalia Mitiushkina, Alexandr A. Romanko, Elena Preobrazhenskaya, Vladislav Tiurin, Tatiana Ermachenkova, Alexandr S. Martianov, Rimma S. Mulkidjan, Tatiana N. Sokolova, Maksim M. Kholmatov, Ilya Bizin, Alexandr O. Ivantsov, Olga S. Yatsuk, Olga A. Zaitseva, Aglaya G. Iyevleva, Ekatherina Sh Kuligina, Evgeny N. Imyanitov
Summary: The study analyzed ALK/ROS1 fusions and 5'-/3'-end unbalanced expression in NSCLC samples. It demonstrated that variant-specific PCR tests can detect common ALK and ROS1 rearrangements, with additional rare ALK fusions identified by PCR or NGS. While unbalanced gene expression can comprehensively analyze ALK, it is more complicated for the detection of ROS1 fusions, suggesting that variant-specific PCR assays are preferable for ROS1 testing.
Article
Pathology
Aigul R. Venina, Alexandr O. Ivantsov, Aglaya G. Iyevleva, Ekaterina Sh Kuligina, Elena Preobrazhenskaya, Dmitry O. Yurlov, Karen Eleanor Rawlinson, Artem Kosmin, Nikita A. Savelov, Grigory A. Raskin, Evgeny N. Imyanitov
Summary: PD-L1 RNA expression measured by PCR and IHC scores obtained by different commercial assays have a moderate correlation. PCR testing shows a high negative predictive value towards IHC analysis, and some NSCLCs have detectable PD-L1 expression on the level of RNA but fall below commonly accepted cut-offs by IHC. Further investigation is needed to determine the reasons for these discrepancies and the clinical sensitivity of these tumors to immune therapy.
ANNALS OF DIAGNOSTIC PATHOLOGY
(2022)
Meeting Abstract
Oncology
E. Imyanitov, A. Anuskina, A. G. Iyevleva, N. V. Mitiushkina, R. Mulkidzhan, E. Preobrazhenskaya, A. Romanko, E. Saitova, V. Tiurin
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
E. Imyanitov, F. Zagrebin, R. Mulkidzhan, E. Krivosheeva, E. Saitova, A. G. Iyevleva, I. Bizin, E. Preobrazhenskaya
ANNALS OF ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Anna P. Sokolenko, Fedor V. Moiseyenko, Aglaya G. Iyevleva, Alexandr O. Ivantsov, Georgiy D. Dolmatov, Ksenia V. Shelekhova, Elizaveta V. Gulo, Anastasya X. Topal, Elizaveta V. Artemieva, Nuriniso H. Abduloeva, Nikita A. Rysev, Daria A. Barsova, Natalia V. Levchenko, Nikita M. Volkov, Vitaliy V. Egorenkov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Summary: Neoadjuvant chemotherapy can lead to complete elimination of visible cancer cells in breast cancer patients. The use of ultrasensitive genetic methods can help detect residual cancer cells. This study focused on BRCA1 mutation carriers to examine the presence of residual cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Aleksandr S. Martianov, Natalia V. Mitiushkina, Anastasia N. Ershova, Darya E. Martynenko, Mikhail G. Bubnov, Priscilla Amankwah, Grigory A. Yanus, Svetlana N. Aleksakhina, Vladislav I. Tiurin, Aigul R. Venina, Aleksandra A. Anuskina, Yuliy A. Gorgul, Anna D. Shestakova, Mikhail A. Maidin, Alexey M. Belyaev, Liliya S. Baboshkina, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Summary: This study analyzed the factors influencing the distribution of actionable genetic alterations in colorectal carcinomas. The study found that there were differences in the distribution of certain genetic alterations based on patients' age and gender. BRAF mutation frequency also showed geographic variation. In addition, a small fraction of CRCs had simultaneous alterations in more than one driver gene.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Meeting Abstract
Oncology
Kristina V. Orlova, Evgeny Ledin, Natalia V. Zhukova, Rashida Orlova, Svetlana Protsenko, Alexey Novik, Fedor Vladimirovich Moiseenko, David Naskhletashvili, Lev V. Demidov
JOURNAL OF CLINICAL ONCOLOGY
(2022)